Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. 1983

G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber

Animal experiments have suggested that salt-balance, prostaglandin synthesis, and renal function are important determinants of the nondiuretic vascular effects of furosemide. To investigate the influence of these factors in humans, we studied 10 normal volunteers and five anephric patients. The volunteers were studied on three occasions: when on a 10 mEq/day sodium diet, on a 250 mEq/day sodium diet, and on a 10 mEq/day sodium diet with indomethacin, 200 mg/day. The anephric patients were studied immediately after dialysis. Plethysmographic methods were used to measure venous capacitance and blood flow in the calf before, and at 5, 10, and 15 minutes after furosemide, 80 mg, iv. Blood was obtained before and 15 minutes after furosemide for determination of plasma renin activity by radioimmunoassay and of plasma 6-keto-prostaglandin F1 alpha by chromatography-mass spectrometry. We found that furosemide significantly increased venous capacitance in the calf of the normal volunteers on a low salt diet. Indomethacin, high salt intake, or lack of renal function was sufficient to inhibit this effect. Plasma renin activity increased only in the group that had the increase in venous capacitance. Limb blood flow decreased gradually in the 15 minutes following administration of furosemide in the normal volunteers, regardless of salt balance or indomethacin, but remained unchanged in the anephric patients. Plasma 6-keto-prostaglandin F1 alpha was less than 30 pg/ml in all samples. Indomethacin concentration averaged 1.3 micrograms/ml in volunteers on the drug. To determine whether indomethacin, salt intake or renal function affected another venodilator, we studied an additional group of normal and uremic volunteers who received 0.6 mg nitroglycerin sublingually.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007866 Leg The inferior part of the lower extremity between the KNEE and the ANKLE. Legs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010991 Plethysmography Recording of change in the size of a part as modified by the circulation in it. Plethysmographies
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive

Related Publications

G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
January 1984, Urologia internationalis,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
January 1987, Indian journal of physiology and pharmacology,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
April 1983, Federation proceedings,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
March 1982, Acta endocrinologica,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
July 1977, The Journal of pharmacology and experimental therapeutics,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
January 1988, Arzneimittel-Forschung,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
August 1976, Archives of oto-rhino-laryngology,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
February 1982, Kidney international,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
September 2005, The Journal of physiology,
G D Johnston, and W R Hiatt, and A S Nies, and N A Payne, and R C Murphy, and J G Gerber
June 1979, Archives internationales de pharmacodynamie et de therapie,
Copied contents to your clipboard!